Abstract
Objective: The purpose of this study was to evaluate the impact of pharmacist counseling on patients purchasing naloxone and to highlight reasons for naloxone purchase refusal.
Design: A multisite study that was conducted from September 15, 2022, to January 11, 2023.
Setting: Independent community pharmacies.
Patients/participants: Fifty patients met inclusion criteria. Data collected included demographics, preintervention knowledge assessment, post-intervention naloxone purchase, and reasons for naloxone refusal.
Outcome measures: The primary outcome was naloxone purchase after pharmacist education intervention. The secondary outcome was reasons for naloxone purchase refusal.
Results: The primary outcome showed that 60 percent of patients purchased naloxone after pharmacist intervention. As a secondary outcome, the number of patients who refused to purchase naloxone was 20 percent, with the majority of patients expressing that naloxone was not necessary as a reason for refusal.
Conclusion: More studies are needed in order to conclude the impact of pharmacist education on the increasing purchase of naloxone.
Publisher
Weston Medical Publishing
Reference15 articles.
1. Rutkow L, Vernick JS: Emergency legal authority and the opioid crisis. N Engl J Med. 2017; 377(26): 2512-2514.
2. Centers for Disease Control and Prevention: Understanding the opioid overdose epidemic. Available at https://www.cdc.gov/opioids/basics/epidemic.html#:~:text=from%201999%E2%80%932020%2C%20more%20than,outlined%20in%20three%20distinct%20waves. Accessed May 25, 2023.
3. National Institute on Drug Abuse: Drug overdose death rates. Available at https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates. Accessed May 25, 2023.
4. O'Donnell J, Gladden RM, Mattson CL, et al.: Vital signs: Characteristics of drug overdose deaths involving opioids and stimulants—24 states and the District of Columbia. MMWR Morb Mortal Wkly Rep. 2020; 69(35): 1189-1197.
5. Wheeler E, Jones TS, Gilbert MK, et al. Opioid overdose prevention programs providing naloxone to laypersons—United States. MMWR Morb Mortal Wkly Rep. 2014; 64(23): 631-635.